Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6871 to 6885 of 7680 results

  1. Pegvaliase for treating phenylketonuria [ID1110]

    Discontinued [GID-TA10345]

    Technology appraisal guidance
    Discontinued

  2. Intravenous zanamivir for treating influenza in hospital [ID1196]

    Discontinued [GID-TA10298]

    Technology appraisal guidance
    Discontinued

  3. Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

    Discontinued [GID-TA10332]

    Technology appraisal guidance
    Discontinued

  4. Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

    Discontinued [GID-TA10522]

    Technology appraisal guidance
    Discontinued

  5. Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]

    In development [GID-TA10589] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    In development [GID-TA11357] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    In development [GID-TA11421] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

    In development [GID-TA10779] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. ALXN1840 for treating Wilson disease TS ID 9950

    In development [GID-TA11449] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

    In development [GID-TA10822] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]

    Discontinued [GID-TA10830]

    Technology appraisal guidance
    Discontinued

  12. Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]

    Discontinued [GID-TA10567]

    Technology appraisal guidance
    Discontinued

  13. Etrolizumab for previously treated moderately to severely active Crohn's disease [ID3965]

    Discontinued [GID-TA10870]

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985]

    In development [GID-TA10880] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]

    In development [GID-TA11024] Expected publication date: TBC

    Technology appraisal guidance
    In development